Cargando…

898. Effectiveness and Tolerability of DTG + 3TC in Clinical Practice: Evidence in PLHIV from Real-world Data

BACKGROUND: Randomized controlled trials have shown dolutegravir (DTG) + lamivudine (3TC) to be an efficacious, well-tolerated and durable regimen for treatment-naive and treatment-experienced people living with HIV (PLHIV). Several observational studies have also concluded that it is effective in c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Evitt, Lee A, Kumar, Rahul, Kamath, Rahul, Jha, Diwakar, Parks, Daniel, van Wyk, Jean A, de Ruiter, Annemiek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644882/ http://dx.doi.org/10.1093/ofid/ofab466.1093

Ejemplares similares

1024. Impact of Treatment Adherence on Efficacy of DTG/3TC and DTG + TDF/FTC: Pooled Analysis of the GEMINI 1 and 2 Clinical Trials
por: Ait-Khaled, Mounir, et al.
Publicado: (2020)

Adherence to and Forgiveness of 3TC/DTG in a Real-World Cohort
por: Maggiolo, Franco, et al.
Publicado: (2022)

1284. Suppressed Switch to DTG/3TC 2-Drug Regimen Vs. BIC- or DTG-Based 3-Drug Regimens
por: Pierone, Gerald, et al.
Publicado: (2022)

Effectiveness and safety of dolutegravir two‐drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta‐analysis of real‐world evidence
por: Punekar, Y S, et al.
Publicado: (2021)

HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review
por: Patel, Rickesh, et al.
Publicado: (2021)

48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naïve adults living with HIV: A multicenter real-life cohort
por: Cabello-Ubeda, Alfonso, et al.
Publicado: (2022)

900. Switching to DTG/3TC Fixed-Dose Combination (FDC) Is Non-inferior to Continuing a TAF-Based Regimen (TBR) in Maintaining Virologic Suppression Through 144 Weeks (TANGO Study)
por: Osiyemi, Olayemi, et al.
Publicado: (2021)

Cost-effectiveness of DTG+ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States
por: Peng, Siyang, et al.
Publicado: (2014)

48 week bone marker changes with Dolutegravir (DTG) plus Abacavir/Lamivudine (ABC/3TC) vs. Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): the SINGLE trial
por: Yazdanpanah, Y, et al.
Publicado: (2014)

69. Incidence of metabolic complications among treatment-naïve adults living with HIV-1 randomized to B/F/TAF, DTG/ABC/3TC or DTG+F/TAF after 144 Weeks
por: Daar, Eric, et al.
Publicado: (2021)

Predict the Effects of Dolutegravir (DTG) Plus Lamivudine (3TC) on Immunological Responses in People Living with HIV (PLWHIV)
por: Troya, Jesús, et al.
Publicado: (2023)

1267. Efficacy and Safety of Switching to DTG/3TC in Virologically Suppressed PLWH by Age, Including Those Aged ≥65 Years: Pooled Results from the TANGO and SALSA Studies
por: Prakash, Manyu, et al.
Publicado: (2022)

Smokeless tobacco use and oral potentially malignant disorders among people living with HIV (PLHIV) in Pune, India: Implications for oral cancer screening in PLHIV
por: Marbaniang, Ivan, et al.
Publicado: (2022)

Piano trios D. 898, D 28
por: Schubert, Franz, 1797-1828
Publicado: (1989)

P898: COMPARISON OF TECLISTAMAB WITH BELANTAMAB MAFODOTIN IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA USING MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON
por: Delforge, M., et al.
Publicado: (2022)

Clinico epidemiological profile of HIV - TB coinfection among PLHIV in coastal south India
por: Bhaskaran, Unnikrishnan
Publicado: (2014)

2842. Durable Efficacy of Two-Drug Regimen (2DR) of Dolutegravir (DTG) plus Lamivudine (3TC) in Antiretroviral Treatment-Naïve Adults with HIV-1 Infection at 96 Weeks: Subgroup Analyses in the GEMINI Studies
por: van Wyk, Jean A, et al.
Publicado: (2019)

Drivers of treatment change in PLHIV- psycho-social factors are more important than considerations of adherence
por: Pitts, Marian, et al.
Publicado: (2012)

The People Living with HIV (PLHIV) Resilience Scale: Development and Validation in Three Countries in the Context of the PLHIV Stigma Index
por: Gottert, A., et al.
Publicado: (2019)

Piano trio no. 1 in B flat, op. 99, D. 898
por: Schubert, Franz, 1797-1828
Publicado: (1982)

319. SWORD 1 and 2: Switch from TDF Containing Regimen to DTG+RPV Maintains Bone Mineral Density and Decreases Bone Turnover Markers Over 148 Weeks
por: Kahl, Lesley, et al.
Publicado: (2019)

P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS
por: Silvennoinen, Raija, et al.
Publicado: (2023)

75. High Rates of Virologic Suppression with DTG/3TC in Newly Diagnosed Adults with HIV-1 Infection and Baseline Viral Load >500,000 c/mL: 48-Week Subgroup Analysis of the STAT Study
por: Rolle, Charlotte-Paige M, et al.
Publicado: (2021)

898. Prevalence of Extended Spectrum Beta-Lactamase Producing Escherichia coli, Klebsiella Pneumoniae and Pseudomonas Aeruginosa from Hospital Acquired Surgical Site Infections in Ghana
por: Egyir, Beverly, et al.
Publicado: (2020)

Leveraging mHealth for the Treatment and Management of PLHIV
por: Kruse, Clemens Scott, et al.
Publicado: (2023)

Data on FTIR, TGA – DTG, DSC of invasive pennisetum purpureum grass
por: Reza, Md Sumon, et al.
Publicado: (2020)

MUDANÇA PARA DTG/3TC EM COMBINAÇÃO DE DOSE FIXA FOI NÃO‐INFERIOR À CONTINUIDADE DE ESQUEMA BASEADO EM TAF (TBR) NA MANUTENÇÃO DA SUPRESSÃO VIRAL POR 96 SEMANAS (ESTUDO TANGO)
por: Wyk, Jean Van, et al.
Publicado: (2021)

898. Influenza Surveillance in the US Veterans Health Administration (VHA): 2022-2023 Season
por: Lucero-Obusan, Cynthia A, et al.
Publicado: (2023)

Patterns of genic intolerance of rare copy number variation in 59,898 human exomes
por: Ruderfer, Douglas M., et al.
Publicado: (2016)

A Novel RET D898Y Germline Mutation in a Patient with Pheochromocytoma
por: Yi, Jin Wook, et al.
Publicado: (2018)

$\pi ^{-} p\rightarrow\pi ^{-} p $ differential cross-section at 898 MeV/c
por: Bradamante, Franco, et al.
Publicado: (1969)

P1284: LIQUID BIOPSY BY ULTRA-DEEP SEQUENCING PLUS PET-TC MONITORING IN REAL-LIFE FOLLICULAR LYMPHOMA PATIENTS
por: Jiménez-Ubieto, A., et al.
Publicado: (2022)

Minority M184V variants in women exposed to 3TC/FTC-containing lopinavir-ritonavir (LPVr) regimens in pregnancy
por: Surah, S, et al.
Publicado: (2010)

An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor–based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1
por: Evitt, Lee A., et al.
Publicado: (2023)

1017. Haves vs. Have-Nots in Healthcare Communication: Examining the Paradox Where PLHIV Who Need Quality Discussions with their Providers the Most, Access it the Least
por: Rios, Patricia De Los, et al.
Publicado: (2020)

1274. Implementation of Pharmacist-led Medication Reconciliation in Older PLHIV
por: Karris, Maile Y, et al.
Publicado: (2022)

Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study
por: Giacomelli, Andrea, et al.
Publicado: (2021)

Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses
por: Pham, Hanh T., et al.
Publicado: (2016)

Thermal characteristics and combustion reactivity of coronavirus face masks using TG-DTG-MS analysis
por: Manić, Nebojša, et al.
Publicado: (2022)

60: The real-world effectiveness of U.S. CF newborn screening
por: Rosenfeld, M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p0gtlk41lgc36ggj8utimu9lvd